DECIPHERA PHARMACEUT

DCPH
Delayed Quote. Delayed  - 12/03 04:00:00 pm
8USD -2.79%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 3 249468
Entreprise Value (EV)1 2 697395
P/E ratio -11,9x-1,57x
Yield --
Capitalization / Revenue 77,2x4,91x
EV / Revenue 64,1x4,14x
EV / EBITDA -10,0x-1,33x
Price to Book 6,05x1,52x
Nbr of stocks (in thousands) 56 93358 481
Reference price (USD) 57,18,00
Announcement Date 02/09/2021-
Previous period Next period
1 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 42,195,3
EBITDA1 -269-296
Operating profit (EBIT)1 -271-295
Operating Margin -644%-310%
Pre-Tax Profit (EBT)1 -266-302
Net income1 -266-295
Net margin -633%-310%
EPS2 -4,78-5,08
Dividend per Share --
Announcement Date 02/09/2021-
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 --
Net Cash position1 55273,0
Leverage (Debt / EBITDA) 2,05x0,25x
Free Cash Flow1 -245-237
ROE (Net Profit / Equities) -48,9%-70,3%
Shareholders' equity1 545420
ROA (Net Profit / Asset) -42,1%-56,4%
Assets1 632523
Book Value Per Share2 9,445,27
Cash Flow per Share --
Capex1 5,325,00
Capex / Sales 12,6%5,25%
Announcement Date 02/09/2021-
Previous period Next period
1 USD in Million
2 USD
Financial Ratios
Size 2021e 2022e
Capitalization 468 M $ -
Entreprise Value (EV) 395 M $ 314 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) -1,57x -2,53x
Capitalization / Revenue 4,91x 3,99x
EV / Revenue 4,14x 3,37x
EV / EBITDA -1,33x -1,56x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 1,52x 2,09x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -310% -162%
Operating Leverage (Delta EBIT / Delta Sales) - 1,56x
Net Margin (Net Profit / Revenue) -310% -161%
ROA (Net Profit / Asset) -56,4% -66,9%
ROE (Net Profit / Equities) -70,3% -93,5%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   5,25% 6,83%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 5,49x 2,41x
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend